X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (123124) 123124
Newsletter (25160) 25160
Newspaper Article (7805) 7805
Magazine Article (1207) 1207
Dissertation (788) 788
Book Chapter (609) 609
Transcript (568) 568
Web Resource (237) 237
Book / eBook (155) 155
Conference Proceeding (99) 99
Streaming Video (93) 93
Publication (81) 81
Government Document (51) 51
Reference (35) 35
Report (31) 31
Journal / eJournal (25) 25
Book Review (23) 23
Trade Publication Article (16) 16
Paper (14) 14
Data Set (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (80570) 80570
hepatitis c (55609) 55609
hepatitis c virus (53896) 53896
male (41015) 41015
female (39781) 39781
middle aged (32257) 32257
adult (31881) 31881
health aspects (21687) 21687
gastroenterology & hepatology (20743) 20743
research (19405) 19405
hepatitis (18204) 18204
infection (17220) 17220
aged (16581) 16581
interferon (15554) 15554
hepacivirus - genetics (13969) 13969
risk factors (13900) 13900
antiviral agents - therapeutic use (13700) 13700
medical research (12452) 12452
liver (12178) 12178
hepatitis c, chronic - drug therapy (12079) 12079
prevalence (11838) 11838
medicine, experimental (11587) 11587
hepatitis-c virus (11298) 11298
infectious diseases (11162) 11162
virology (10996) 10996
care and treatment (10984) 10984
virus diseases (10694) 10694
hiv (10665) 10665
hepatitis c - complications (10227) 10227
hepatitis c - epidemiology (10199) 10199
analysis (10171) 10171
antiviral agents (10086) 10086
genotype (9568) 9568
ribavirin (9047) 9047
treatment outcome (8706) 8706
immunology (8698) 8698
adolescent (8465) 8465
hcv (8401) 8401
animals (8195) 8195
infections (7964) 7964
biological response modifiers (7783) 7783
interferon-alpha - therapeutic use (7736) 7736
cirrhosis (7385) 7385
hepatitis c - drug therapy (7375) 7375
hepatitis b (7281) 7281
hepatitis c, chronic - complications (7269) 7269
viruses (7150) 7150
drug therapy (7103) 7103
virus-infection (7033) 7033
hepatitis c - virology (6974) 6974
therapy (6818) 6818
drug therapy, combination (6817) 6817
liver cirrhosis (6741) 6741
hepatitis-c (6725) 6725
rna (6679) 6679
communicable diseases (6595) 6595
liver diseases (6464) 6464
hepatitis c - diagnosis (6325) 6325
chronic hepatitis-c (6318) 6318
genetic aspects (6290) 6290
hepacivirus - immunology (6180) 6180
transplantation (6131) 6131
ribavirin - therapeutic use (6080) 6080
medicine, general & internal (6001) 6001
retrospective studies (5949) 5949
hepacivirus - isolation & purification (5924) 5924
epidemiology (5740) 5740
fibrosis (5660) 5660
hepatitis c - transmission (5536) 5536
hepatitis c, chronic - virology (5457) 5457
hepatitis c - immunology (5410) 5410
young adult (5308) 5308
hepatocellular carcinoma (5246) 5246
recombinant proteins (5228) 5228
disease (5092) 5092
gastroenterology and hepatology (5076) 5076
microbiology (5045) 5045
rna, viral - blood (5030) 5030
universities and colleges (4993) 4993
hepatocellular-carcinoma (4978) 4978
diagnosis (4896) 4896
chronic hepatitis c (4850) 4850
liver - pathology (4827) 4827
hepacivirus - drug effects (4806) 4806
pharmacology & pharmacy (4677) 4677
surgery (4673) 4673
hiv infections - complications (4525) 4525
viral load (4460) 4460
risk (4443) 4443
liver cancer (4415) 4415
time factors (4252) 4252
liver transplantation (4148) 4148
patients (4132) 4132
hepatitis b virus (4118) 4118
biopsy (4093) 4093
antibodies (4065) 4065
virus (4061) 4061
cancer (4038) 4038
digestive system diseases (4026) 4026
polymerase chain reaction (4012) 4012
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (191) 191
Gerstein Science - Stacks (41) 41
Robarts - Government Pubs (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
Scarborough Hospital - Online (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
UTL at Downsview - May be requested (2) 2
Gerstein Science - Library use only (1) 1
Gerstein Science - Periodical Stacks (1) 1
Media Commons - Audio Visual (1) 1
Robarts - Stacks (1) 1
St. Michael's Hospital - Online (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (143971) 143971
French (6381) 6381
Spanish (2234) 2234
Japanese (1983) 1983
German (1646) 1646
Chinese (1072) 1072
Russian (906) 906
Korean (765) 765
Portuguese (578) 578
Italian (490) 490
Polish (458) 458
Hungarian (250) 250
Turkish (196) 196
Czech (172) 172
Croatian (78) 78
Danish (54) 54
Swedish (54) 54
Romanian (53) 53
Serbian (49) 49
Dutch (45) 45
Persian (37) 37
Norwegian (35) 35
Slovak (26) 26
Hebrew (22) 22
Bosnian (14) 14
Finnish (14) 14
Ukrainian (14) 14
Arabic (13) 13
Icelandic (11) 11
Indonesian (9) 9
Bulgarian (7) 7
Slovenian (7) 7
Catalan (6) 6
Lithuanian (6) 6
Azerbaijani (2) 2
Belarusian (2) 2
Breton (2) 2
Albanian (1) 1
Macedonian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Investigation, ISSN 0021-9738, 01/2011, Volume 121, Issue 1, pp. 308 - 317
Chronic infection with hepatitis C virus (HCV) is a major public health problem, with nearly 170 million infected individuals worldwide Current treatment for... 
MEDICINE, RESEARCH & EXPERIMENTAL | LIVER INFLAMMATION | GAMMA-INDUCIBLE PROTEIN-10 | VIRUS-INFECTION | DIPEPTIDYL-PEPTIDASE-IV | ANTIVIRAL THERAPY | INSULIN-RESISTANCE | IMMUNE-RESPONSES | CHRONIC HEPATITIS-C | LEVELS CORRELATE | PEGINTERFERON PLUS RIBAVIRIN | Chemokine CXCL10 - blood | Prognosis | Antiviral Agents - therapeutic use | Receptors, CXCR3 - blood | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Chemokine CXCL10 - antagonists & inhibitors | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Hepatitis C, Chronic - therapy | Recombinant Proteins | Hepatitis C, Chronic - blood | Polyethylene Glycols - therapeutic use | T-Lymphocytes - virology | Treatment Failure | Hepatitis C, Chronic - immunology | Peptide Fragments - blood | Protein Array Analysis | T-Lymphocytes - immunology | Proteases | Physiological aspects | Research | Diagnosis | Hepatitis C | Drug therapy | Chemokines | Hepatitis C, Chronic/therapy | T-Lymphocytes/immunology | Polyethylene Glycols/therapeutic use | Dipeptidyl Peptidase 4/blood | Receptors, CXCR3/blood | Chemokine CXCL10/blood | T-Lymphocytes/virology | Hepatitis C, Chronic/blood | Interferon-alpha/therapeutic use | Chemokine CXCL10/antagonists & inhibitors | Life Sciences | Immunology | Antiviral Agents/therapeutic use | Hepatitis C, Chronic/immunology | Peptide Fragments/blood | Ribavirin/therapeutic use | Hepatitis C, Chronic/virology
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133236
Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy.... 
VIRUS-INFECTION | CHEMOKINES | MULTIDISCIPLINARY SCIENCES | CHRONIC HEPATITIS-C | PROTEIN-10 | GENOTYPE 1 INFECTION | PREDICTIVE-VALUE | RIBAVIRIN | INDUCTION | ASSOCIATION | SPONTANEOUS CLEARANCE | Recurrence | Interferons | Humans | Fluorenes - therapeutic use | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Male | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Virus Replication - drug effects | Chemokine CXCL10 - blood | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Dipeptidyl Peptidase 4 - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Convalescence | Chemokine CXCL10 - genetics | Protein Processing, Post-Translational | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Infection | Care and treatment | Analysis | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Therapy | Laboratories | Chronic infection | Critical care | Amino acids | Infections | Ribavirin | Clinical outcomes | Proteins | Genotype & phenotype | Hepatitis | Immunology | Hepatology | Post-translation | Pretreatment | Drug dosages | Genotypes | Statistical analysis | Liver diseases | Dendritic cells | Serum levels | Studies | Infectious diseases | CXCL10 protein | Biomarkers | Chemokines | Virus Replication/drug effects | Viral Load/drug effects | Dipeptidyl Peptidase 4/blood | Dipeptidyl Peptidase 4/genetics | Chemokine CXCL10/blood | Hepatitis C, Chronic/blood | Life Sciences | Hepatitis C, Chronic/drug therapy | Hepatitis C, Chronic/virology | Hepatitis C, Chronic/genetics | Chemokine CXCL10/genetics | Benzimidazoles/therapeutic use | Hepacivirus/physiology | Fluorenes/therapeutic use | Antiviral Agents/therapeutic use | Sofosbuvir/therapeutic use | Hepacivirus/drug effects | Ribavirin/therapeutic use
Journal Article
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2007, Volume 104, Issue 14, pp. 6025 - 6030
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 1, pp. 320 - 325.e2
Background & Aims Polymorphisms in the interleukin-28B ( IL28B ) gene are associated with outcomes from infection with hepatitis C virus (HCV). However, the... 
Gastroenterology and Hepatology | Genetics | Liver Disease | Protective Mechanisms | Killer Cell Immunoglobulin-Like Receptor | CLEARANCE | INHIBITORY RECEPTOR GENES | INJECTION-DRUG USERS | REPLICATION | HEPATITIS-C VIRUS | APPARENT RESISTANCE | IMMUNE-RESPONSES | HLA | GASTROENTEROLOGY & HEPATOLOGY | Hepacivirus - immunology | Humans | Middle Aged | Immunity, Innate - genetics | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Hepatitis C - immunology | Interleukins - genetics | Hepatitis C Antibodies - blood | Adult | Female | Hepatitis C - prevention & control | Odds Ratio | Substance Abuse, Intravenous - complications | Genetic Predisposition to Disease | Receptors, KIR2DL3 - genetics | Risk Assessment | Gene Frequency | Risk Factors | Hepatitis C, Chronic - prevention & control | Hepatitis C - genetics | Logistic Models | United Kingdom | Hepatitis C, Chronic - diagnosis | Disease Progression | Hepatitis C - diagnosis | Phenotype | Hepatitis C, Chronic - immunology | Remission, Spontaneous | Polymorphism, Single Nucleotide | HLA-C Antigens - genetics | Hepatitis C, Chronic - genetics | Medical colleges | Immunogenetics | Biological products | Histocompatibility antigens | RNA | HLA histocompatibility antigens | Genetic aspects | Biological response modifiers | Hepatitis C | Hepatitis C virus | Health aspects | IFN, interferon | HLA, human leukocyte antigen | Hencore, Hepatitis C European Network for Cooperative Research collaboration | Original Research | HCV, hepatitis C virus | EU, exposed but uninfected | HLA-C1, group 1 HLA-C allotype | KIR, killer cell immunoglobulin-like receptor | SNP, single nucleotide polymorphism | NK, natural killer cells | IDU, injection drug users | SR, spontaneous resolvers
Journal Article
Journal of the International AIDS Society, ISSN 1758-2652, 2017, Volume 20, Issue 1, pp. 21856 - n/a
Introduction: A lack of access to hepatitis C virus (HCV) diagnostics is a significant barrier to achieving the World Health Organization 2030 global... 
hepatitis C virus (HCV) | screening | HCV core antigen | dried blood spot | people who inject drugs | Africa | INFECTIOUS DISEASES | BARRIERS | PREVALENCE | IMMUNOLOGY | HIV | C VIRUS-INFECTION | POINT-OF-CARE | USERS | HEPATITIS-C | Hepacivirus - isolation & purification | Humans | Tanzania | Hepacivirus - genetics | Hepatitis C Antigens - metabolism | Genotype | Male | Phylogeny | Hepatitis C Antigens - analysis | Viral Load | Hepatitis C - diagnosis | RNA, Viral - genetics | Dried Blood Spot Testing - methods | Hepatitis C - blood | Sensitivity and Specificity | Viral Core Proteins - genetics | Hepatitis C - virology | Viral Core Proteins - metabolism | Hepatitis C Antigens - genetics | Adult | Female | Hepacivirus - physiology | Viral Core Proteins - analysis | Antigens | Spermatozoa | Hepatitis C virus | Health aspects | Antiviral agents | Serum | Dosage and administration | Research | Studies | Hepatitis | Accuracy | Automation | Statistical analysis | Acquired immune deficiency syndrome--AIDS | Laboratories | Human immunodeficiency virus--HIV | Population | Infections | Viral Core Proteins / metabolism | Viral Core Proteins / analysis | Dried Blood Spot Testing / methods | Life Sciences | Hepatitis C Antigens / metabolism | Hepatitis C / virology | Hepacivirus / isolation & purification | Hepacivirus / genetics | Hepatitis C Antigens / analysis | Hepacivirus / physiology | Hepatitis C / blood | Viral Core Proteins / genetics | Hepatitis C / diagnosis | Hepatitis C Antigens / genetics | RNA, Viral / genetics | Santé publique et épidémiologie
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2019, Volume 393, Issue 10178, pp. 1319 - 1329
The revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the... 
GENOTYPE 1 | TODAYS TREATMENT PARADIGM | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | INJECT DRUGS | PEOPLE | HCV | FUTURE DISEASE BURDEN | EXTRAHEPATIC MANIFESTATIONS | NATURAL-HISTORY | VIRAL-HEPATITIS | Hepacivirus - drug effects | Models, Theoretical | Prevalence | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Humans | Mortality | Hepatitis C, Chronic - prevention & control | India - epidemiology | China - epidemiology | Hepatitis C, Chronic - drug therapy | Mass Screening - methods | Incidence | Hepatitis C, Chronic - transmission | Pakistan - epidemiology | World Health Organization - organization & administration | Health Services Accessibility | Hepatitis C - epidemiology | Hepatitis C, Chronic - epidemiology | Hepatitis C - prevention & control | Hepatitis C - transmission | Prevention | Liver cancer | Antiviral agents | Care and treatment | Analysis | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Epidemiology | Intervention | Epidemics | Drug abuse | Substance abuse treatment | Demography | Funding | Liver | Viruses | Infections | Blood | Ribavirin | Hepatitis | Reduction | Scaling up | Population | Mathematical models | Diagnosis | Safety | Public health | Sensitivity analysis | Health risks | Risk reduction | Disease control | Screening | Cirrhosis | Fatalities | Scaling | Interferon | Risk management | Cancer
Journal Article